Literature DB >> 16294265

Critical role of beta3 integrin in experimental postmenopausal osteoporosis.

Haibo Zhao1, Hideki Kitaura, Mark S Sands, F Patrick Ross, Steven L Teitelbaum, Deborah Veis Novack.   

Abstract

UNLABELLED: We show that mice lacking beta3 integrin are protected from OVX-induced bone loss. Using a lentiviral-based strategy to express beta3 mutants in beta3(-/-) mice, we also show that beta3(S752), but not beta3(Y747/Y759), is important for osteoclastic bone resorption in vivo.
INTRODUCTION: Mice lacking the beta3 integrin have dysfunctional osteoclasts and therefore accumulate bone mass with age. Thus, the alphavbeta3 integrin is a potential anti-osteoporosis target. Identifying components of the beta3 integrin that determine its function in vivo is essential for therapeutically exploiting the antiresorptive properties of alphavbeta3.
MATERIALS AND METHODS: We used DXA and histomorphometry to assess bone loss after ovariectomy in wildtype and beta3 integrin null mice. We used lentiviral vectors carrying various human beta3 (hbeta3) integrin constructs to transduce beta3(-/-) bone marrow and reconstituted lethally irradiated beta3(-/-) mice with the transduced marrow. The expressed constructs include the intact integrin and two mutants, namely hbeta3(Y747F/Y759F) and hbeta3(S752P), each of which induces the bleeding dyscrasia, Glanzmann's thrombasthenia, in humans. Two months after transplantation, the expression of hbeta3 was measured by flow cytometry of marrow-derived macrophages. Osteoclast differentiation and function were assessed ex vivo by TRACP and actin-ring staining, respectively. Reconstituted mice were ovariectomized, and bone loss was assessed by DXA, histomorphometry, and serum TRACP5b assay.
RESULTS: beta3(-/-) mice are protected from ovariectomy-induced bone loss, showing no difference in BMD compared with sham-operated controls. We successfully expressed hbeta3 integrins in beta3(-/-) hosts using lentiviral transduction of bone marrow. Two months after transplantation, 25-35% of marrow-derived macrophages expressed the hbeta3 constructs. Similar to its effect in vitro, hbeta3(WT) completely rescued the osteoclast and platelet phenotype of beta3(-/-) mice. Whereas platelet function remained deranged in beta3(-/-) mice overexpressing hbeta3(Y747F/Y759F), osteoclast function was fully restored. In contrast, beta3(-/-) mice expressing hbeta3(S752P) continued to exhibit prolonged bleeding times and dysfunctional osteoclasts in vitro and ex vivo. Most importantly, hbeta3(WT) and hbeta3(Y747F/Y759F) transplanted mice underwent equivalent ovariectomy-induced bone loss, whereas, like those bearing the control vector, hbeta3(S752P) transplanted mice were protected.
CONCLUSIONS: Functional beta3 integrin is required for ovariectomy-induced bone loss. beta3(S752), but not beta3(Y747/Y759), is critical for osteoclast function in vivo.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16294265     DOI: 10.1359/JBMR.050724

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  25 in total

Review 1.  New targets for intervention in the treatment of postmenopausal osteoporosis.

Authors:  E Michael Lewiecki
Journal:  Nat Rev Rheumatol       Date:  2011-09-20       Impact factor: 20.543

2.  Cdc42 regulates bone modeling and remodeling in mice by modulating RANKL/M-CSF signaling and osteoclast polarization.

Authors:  Yuji Ito; Steven L Teitelbaum; Wei Zou; Yi Zheng; James F Johnson; Jean Chappel; F Patrick Ross; Haibo Zhao
Journal:  J Clin Invest       Date:  2010-05-24       Impact factor: 14.808

3.  Osteoclasts: what do they do and how do they do it?

Authors:  Steven L Teitelbaum
Journal:  Am J Pathol       Date:  2007-02       Impact factor: 4.307

4.  Disruption of CXCR4 enhances osteoclastogenesis and tumor growth in bone.

Authors:  Angela C Hirbe; Jessica Rubin; Ozge Uluçkan; Elizabeth A Morgan; Mark C Eagleton; Julie L Prior; David Piwnica-Worms; Katherine N Weilbaecher
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-22       Impact factor: 11.205

Review 5.  Targeting integrins to promote bone formation and repair.

Authors:  Pierre J Marie
Journal:  Nat Rev Endocrinol       Date:  2013-01-29       Impact factor: 43.330

6.  Osteoclast-Primed Foxp3+ CD8 T Cells Induce T-bet, Eomesodermin, and IFN-γ To Regulate Bone Resorption.

Authors:  Elena V Shashkova; Jahnavi Trivedi; Anna B Cline-Smith; Chloe Ferris; Zachary S Buchwald; Jesse Gibbs; Deborah Novack; Rajeev Aurora
Journal:  J Immunol       Date:  2016-06-20       Impact factor: 5.422

7.  Novel Pure αVβ3 Integrin Antagonists That Do Not Induce Receptor Extension, Prime the Receptor, or Enhance Angiogenesis at Low Concentrations.

Authors:  Jihong Li; Yoshiyuki Fukase; Yi Shang; Wei Zou; José M Muñoz-Félix; Lorena Buitrago; Johannes van Agthoven; Yixiao Zhang; Ryoma Hara; Yuta Tanaka; Rei Okamoto; Takeshi Yasui; Takashi Nakahata; Toshihiro Imaeda; Kazuyoshi Aso; Yuchen Zhou; Charles Locuson; Dragana Nesic; Mark Duggan; Junichi Takagi; Roger D Vaughan; Thomas Walz; Kairbaan Hodivala-Dilke; Steven L Teitelbaum; M Amin Arnaout; Marta Filizola; Michael A Foley; Barry S Coller
Journal:  ACS Pharmacol Transl Sci       Date:  2019-08-02

8.  Interferon-gamma targets cancer cells and osteoclasts to prevent tumor-associated bone loss and bone metastases.

Authors:  Zhiqiang Xu; Michelle A Hurchla; Hongju Deng; Ozge Uluçkan; Fang Bu; Andrew Berdy; Mark C Eagleton; Emanuela A Heller; Desiree H Floyd; Wessel P Dirksen; Sherry Shu; Yuetsu Tanaka; Soledad A Fernandez; Thomas J Rosol; Katherine N Weilbaecher
Journal:  J Biol Chem       Date:  2008-12-05       Impact factor: 5.157

9.  Loss of Cbl-PI3K interaction in mice prevents significant bone loss following ovariectomy.

Authors:  Naga Suresh Adapala; Danielle Holland; Vanessa Scanlon; Mary F Barbe; Wallace Y Langdon; Alexander Y Tsygankov; Joseph A Lorenzo; Archana Sanjay
Journal:  Bone       Date:  2014-07-01       Impact factor: 4.398

Review 10.  Non-oncological applications of RGD-based single-photon emission tomography and positron emission tomography agents.

Authors:  Thomas Ebenhan; Janke Kleynhans; Jan Rijn Zeevaart; Jae Min Jeong; Mike Sathekge
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-09-12       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.